These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 2403738)

  • 1. Expanding clinical role of unique class III antiarrhythmic effects of sotalol.
    Singh BN
    Am J Cardiol; 1990 Jan; 65(2):84A-88A. PubMed ID: 2403738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arrhythmia control by prolonging repolarization: the concept and its potential therapeutic impact.
    Singh BN
    Eur Heart J; 1993 Nov; 14 Suppl H():14-23. PubMed ID: 7904934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Historical development of the concept of controlling cardiac arrhythmias by lengthening repolarization: particular reference to sotalol.
    Singh BN
    Am J Cardiol; 1990 Jan; 65(2):3A-11A; discussion 35A-36A. PubMed ID: 2403733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electrophysiologic basis for the antiarrhythmic actions of sotalol and comparison with other agents.
    Singh BN
    Am J Cardiol; 1993 Aug; 72(4):8A-18A. PubMed ID: 8346731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Choice and chance in drug therapy of cardiac arrhythmias: technique versus drug-specific responses in evaluation of efficacy.
    Singh BN
    Am J Cardiol; 1993 Nov; 72(16):114F-124F. PubMed ID: 8237824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management.
    Hohnloser SH
    Am J Cardiol; 1997 Oct; 80(8A):82G-89G. PubMed ID: 9354415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The coming of age of the class III antiarrhythmic principle: retrospective and future trends.
    Singh BN
    Am J Cardiol; 1996 Aug; 78(4A):17-27. PubMed ID: 8780325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlling cardiac arrhythmias by lengthening repolarization: historical overview.
    Singh BN
    Am J Cardiol; 1993 Nov; 72(16):18F-24F. PubMed ID: 8237826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current antiarrhythmic drugs: an overview of mechanisms of action and potential clinical utility.
    Singh BN
    J Cardiovasc Electrophysiol; 1999 Feb; 10(2):283-301. PubMed ID: 10090235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials.
    Lazzara R
    Am J Cardiol; 1996 Aug; 78(4A):28-33. PubMed ID: 8780326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs.
    Singh BN; Wadhani N
    J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S85-97. PubMed ID: 15378133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications.
    Hohnloser SH; Singh BN
    J Cardiovasc Electrophysiol; 1995 Oct; 6(10 Pt 2):920-36. PubMed ID: 8548113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiarrhythmic actions of DL-sotalol in ventricular and supraventricular arrhythmias.
    Singh BN
    J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S75-90. PubMed ID: 1279313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic, pharmacokinetic and antiarrhythmic properties of d-sotalol, the dextro-isomer of sotalol.
    Advani SV; Singh BN
    Drugs; 1995 May; 49(5):664-79. PubMed ID: 7601009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias.
    Fitton A; Sorkin EM
    Drugs; 1993 Oct; 46(4):678-719. PubMed ID: 7506652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is class III antiarrhythmic activity important?
    Singh BN
    Cardiovasc Drugs Ther; 1990 Jun; 4 Suppl 3():597-602. PubMed ID: 2275889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience with sotalol in the treatment of cardiac arrhythmias.
    Kirschenbaum HL; Rosenberg JM
    Clin Ther; 1994; 16(3):346-64. PubMed ID: 7923303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of d-sotalol, a pure class III antiarrhythmic compound, in patients with symptomatic complex ventricular ectopy. Results of a multicenter, randomized, double-blind, placebo-controlled dose-finding study. The d-Sotalol PVC Study Group.
    Hohnloser SH; Meinertz T; Stubbs P; Crijns HJ; Blanc JJ; Rizzon P; Cheuvart B
    Circulation; 1995 Sep; 92(6):1517-25. PubMed ID: 7664435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes.
    Chézalviel-Guilbert F; Davy JM; Poirier JM; Weissenburger J
    J Am Coll Cardiol; 1995 Sep; 26(3):787-92. PubMed ID: 7642874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electrophysiologic properties of sotalol and d-sotalol. A current view.
    Touboul P
    Eur Heart J; 1993 Nov; 14 Suppl H():24-9. PubMed ID: 7904935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.